NVONovo’s pill is doing the heavyweight lifting
Novo Nordisk rolled out new data at ECO2026 showing the company’s oral Wegovy dose — semaglutide 25 mg — is not just shaving pounds, but potentially helping people move better too. In the OASIS 4 trial, nearly a third of adults were early responders, dropping an average of 13.2% of their body weight after four months and 21.6% by the end of the study.
Why investors care
This is the kind of update that makes the obesity race feel less like a sprint and more like a winner-take-most marathon. The more data Novo stacks up behind the pill version of Wegovy, the more it can argue that the franchise isn’t just a shot-only story anymore.
And the mobility angle matters. Nearly eight in 10 participants with poor physical function almost doubled their ability to move compared with placebo — think bending over, standing comfortably, and staying active without feeling like your joints are filing a formal complaint.
The bigger picture
For shareholders, the takeaway is pretty simple:
- more clinical validation for the oral Wegovy program
- a broader potential patient story than weight loss alone
- another reminder that obesity drugs are turning into a full-blown platform war
Big picture: Novo keeps trying to make Wegovy less of a blockbuster and more of a category. That’s the kind of move Wall Street tends to keep on watching.